Actively Recruiting
Cardiogenic Shock Integrated PHenotyping for Event Reduction
Led by Niguarda Hospital · Updated on 2026-04-16
26
Participants Needed
1
Research Sites
400 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this study is to better understand the time course of different biological mechanisms involved in acute decompensated heart failure complicated by cardiogenic shock throughout the evaluation of changes and the relationship among markers of inflammation (IL-6) and markers of increased endothelial permeability (Ang-2) or endothelial glycocalyx perturbation (Syndecan-1 and HS) and throughout a targeted metabolomic approach.
CONDITIONS
Official Title
Cardiogenic Shock Integrated PHenotyping for Event Reduction
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 to less than 75 years, men and women
- Systolic blood pressure below 90 mmHg or mean arterial pressure below 60 mmHg after fluid challenge without fluid overload, or need for vasoactive agents to maintain blood pressure above these values
- Reduced left ventricle systolic function with ejection fraction 35% or less
- At least one sign of overt hypoperfusion such as altered consciousness, cold and sweaty skin, mixed venous oxygen saturation below 60%, arterial lactates above 2 mmol/L, or urine output less than 0.5 ml/kg/hour for at least 6 hours
- No contraindications to heart replacement therapy
You will not qualify if you...
- Cardiogenic shock symptoms lasting more than 6 hours
- Septic shock with clear infection source
- Cardiogenic shock caused by acute myocardial infarction
- Cardiogenic shock caused by acute myocarditis
- Cardiogenic shock caused by pulmonary thromboembolism
- Recurrent major arrhythmias including ventricular tachycardia, ventricular fibrillation, or atrial fibrillation with ventricular rate above 160 bpm
- Severe aortic valve disease
- Obstructive hypertrophic cardiomyopathy, constrictive pericarditis, or severe heart failure from congenital heart disease
- Severe peripheral vascular disease preventing mechanical support insertion
- Cardiogenic shock secondary to cardiac or non-cardiac surgery
- Comorbidities with life expectancy less than one year
- Severe kidney impairment (eGFR below 30 ml/min/1.73 m2), severe chronic obstructive pulmonary disease, or liver cirrhosis
- Pregnancy, breastfeeding, or planning pregnancy during the study
- Any other significant disease or condition that may put the participant at risk or affect study results as judged by the investigator
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda
Milan, Italy, 20162
Actively Recruiting
Research Team
N
Nuccia Morici, MD
CONTACT
A
Alice Sacco, MD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here